transmembrane protein 200AGenealiases: KIAA1913 · TTMA · TTMC
Q-omics provides the consensus-scored TMEM200A profile across patient tissues and cancer cell-line models. TMEM200A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM200A is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, TMEM200A RNA expression shows 21,025 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where TMEM200A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM200A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM200A survival associations across molecular data types. TMEM200A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM200A RNA expression–survival associations across cancer types. High TMEM200A expression shows unfavorable associations in STAD, BLCA, MESO and ACC, but favorable associations in KIRC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM200A RNA expression.
This table summarizes TMEM200A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM200A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM200A shows lower tumor expression in KICH and UCEC and higher tumor expression in KIRC, HNSC, LIHC and STAD. The KIRC box plot shows higher TMEM200A RNA expression in tumor versus normal tissue (log2 FC = +2.159, t-test p < 0.001).
This table shows molecular features associated with TMEM200A in patient tissues and cancer cell lines. In patient samples, TMEM200A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM200A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
